Value-Based Medication Benefits in Diabetes Management

By Staff Writer

February 9, 2024

Introduction

Type 2 diabetes (T2D) is a complex condition that involves inadequate insulin production and irregular blood sugar levels. Over the past two decades, the prevalence of T2D has surged from 10% to 13% in the United States alone. Pharmacotherapy plays a crucial role in managing diabetes and preventing secondary complications. These complications are becoming more prevalent in the working age population. However, the rising costs of medication present a significant barrier to optimal care. In particular for lower-income patients, leading to high out-of-pocket (OOP) payments and non-compliance.

Value-Based Medication Benefits

The average OOP for patients diagnosed with diabetes are between $150 to $500 per year for treatment. To counter the issue of escalating OOP costs, some employers have adopted more generous health insurance designs and policies to counter additional payments. One such initiative is the preventive drug list (PDL) add-on. PDLs allows patients to pay reduced co-payments or deductible amounts for high-value preventive medications, including antidiabetic drugs.

Impact of PDLs on Diabetes Management

Recent studies have found that PDLs are associated with increased preventive medication fills among diabetes patients from lower-income neighbourhoods. On the other hand, there has been a shortage of research that has investigated the correlation between value-based drug benefits and health outcomes.

A recent study from Duke University aimed to address this gap by studying whether PDLs are associated with reduced rates of acute, preventable diabetes complications. The study examined a dataset spanning a 14-year period (2004-2017) and consisting of almost 2.3 million people with diabetes who were covered by commercial insurance.

Key Findings

Patients with diabetes enrolled in a value-based medication benefit increased their antidiabetic medication use. They also experienced 8.4% fewer acute, diabetes complication days compared to controls. Notably, PDL members from lower-income areas, who experienced the largest magnitude increases in antidiabetic medication use, experienced a 10.2% decline in complication days. To the authors knowledge no other studies have been published that examined reduced medication costs in diabetes and its effects. However, in two randomised clinical trials conducted in Canada, it was discovered that the removal of drug co-payments resulted in slight to moderate increases in medication usage.

Limitations and Future Research

While the findings from this study are promising, they are not without limitations, as it only applies to patients with diabetes on commercial health plans. Further, PDL coverage was not randomly assigned, but chosen by certain employers. Finally, the study only examined outcomes associated with PDL enrollment over a single year. For more comprehensive research, larger sample sizes will be necessary to include additional clinical outcomes.

Conclusion

In conclusion, this study indicates that value-based medication benefits not only lowers antidiabetic medication OOP costs, but also shows a 8.4% reduction in preventable diabetes complications. The study results might suggest a strategy that entails incentivising the adoption of targeted cost-sharing reductions. Especially, among commercially insured patients with diabetes and lower income to enhance health outcomes.

 

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.